COMMUNIQUÉS West-GlobeNewswire

Merit Medical Reports Second Quarter 2024 Results and Raises Full-Year Guidance

01/08/2024 - 22:10

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to 9.0% in prior year [...]

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

01/08/2024 - 22:05

Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company [...]

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

01/08/2024 - 22:05

Second quarter total revenue of $147 million, Crysvita ® revenue of $114 million and Dojolvi ® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million NOVATO, Calif., Aug. [...]

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01/08/2024 - 22:05

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent [...]

LeMaitre Q2 2024 Financial Results

01/08/2024 - 22:05

BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided [...]

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

01/08/2024 - 22:05

LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company [...]

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

01/08/2024 - 22:05

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in [...]

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024

01/08/2024 - 22:05

Year-over-year revenue grows 9% , operating profit up 38% , non-GAAP operating profit up 30% Operating cash flow of $440 million Quarterly dividend increases 10% to $0.53 per share Company to host an Investor Day on [...]

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

01/08/2024 - 22:05

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an [...]

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

01/08/2024 - 22:05

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

01/08/2024 - 22:05

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today [...]

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/08/2024 - 22:05

BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on July 31, 2024, the [...]

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

01/08/2024 - 22:05

SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]

T2 Biosystems to Attend Upcoming Investor Conferences

01/08/2024 - 22:05

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in [...]

Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings

01/08/2024 - 22:05

SOUTH JORDAN, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE study. A pivotal, [...]

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

01/08/2024 - 22:05

SALT LAKE CITY, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it completed the sale of its EndoPredict ® business to [...]

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

01/08/2024 - 22:05

- Management will hold a conference call on Thursday, August 8 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company [...]

OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024

01/08/2024 - 22:05

MIAMI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on [...]

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

01/08/2024 - 22:05

FOSTER CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]